Q-omics provides the consensus-scored KRT8 profile across patient tissues and cancer cell-line models. KRT8 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, KRT8 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, KRT8 protein abundance shows 17,900 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight PAAD, KIRP, and BRCA as cancer lineages where KRT8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT8 survival associations across molecular data types. KRT8 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT8 RNA expression–survival associations across cancer types. High KRT8 expression shows unfavorable associations in PAAD, LUAD, LGG, LIHC, ESCA and MESO. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for KRT8 RNA expression.
This table summarizes KRT8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KRT8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT8 shows higher tumor expression in KIRP, LUAD, KIRC, UCEC, STAD and BRCA. The KIRP box plot shows higher KRT8 RNA expression in tumor versus normal tissue (log2 FC = +1.885, t-test p < 0.001).
This table shows molecular features associated with KRT8 in patient tissues and cancer cell lines. In patient samples, KRT8 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
